[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603065":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":12,"responsibleParty":32,"collaborators":7,"id":36,"slug":7,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":54,"overallStatus":15,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Tongji Hospital","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Electronic Patient-Reported Outcome Monitoring","Participants complete the MDASI-LC and EQ-5D questionnaires electronically on a weekly basis during CRT and for 12 weeks after CRT. The data are used to evaluate symptom burden, symptom clusters, and symptom trajectories.",[13],{"facility":14,"status":15,"city":16,"state":17,"zip":18,"country":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei","430030","China",{"type":21,"coordinates":22},"Point",[23,24],114.26667,30.58333,{"lat":24,"lon":23},[27],{"name":28,"role":29,"phone":30,"phoneExt":7,"email":31},"Qian Chu, MD, PhD","CONTACT","027-69378806","qchu@hust.edu.cn",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Qian Chu","Professor","100603065",false,"NCT07131670","Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","A Prospective Observational Study on Symptom Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes","ePRO-LC-CRT","Inclusion Criteria:\n\n* Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC\n* Age ≥ 18 years\n* Receiving definitive chemoradiotherapy\n* Able and willing to complete electronic questionnaires\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Severe comorbidities (heart, liver, kidney)\n* Psychiatric illness or cognitive impairment\n* Prior chest or mediastinal radiotherapy","ALL","18 Years",{"count":46,"type":47},100,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.",[51,52,53],"Lung Cancer","Chemoradiotherapy","Patient-Reported Outcomes (PRO)",[55,56,57,58,51,59],"Symptom Burden","Symptom Clusters","Electronic Patient-Reported Outcomes","MDASI-LC","EQ-5D","2025-08-12",{"date":62,"type":63},"2025-08-20","ACTUAL",{"date":65,"type":63},"2024-06-01",{"date":67,"type":47},"2026-03-31",{"name":34,"class":6},1]